Does a 5-day course of antibiotics in elderly patients with community-acquired pneumonia achieve the established criteria of clinical stability? - 08/05/21
, M. Dinia b, N. Raulet b, S. Sayegh c, S. Diamantis a, M. Jager bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 3 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Short-course (<7 days) antibiotic treatment for community-acquired pneumonia (CAP) is safe in young adults, according to several studies. There is a lack of data on how applicable this strategy would be in elderly patients. |
• | We observed that in half of patients aged 75 and older, hospitalised for CAP, a 5-day antibiotic course was appropriate, according to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for clinical stability. |
Abstract |
Objective |
We aimed to determine the proportion of elderly patients hospitalised for community-acquired pneumonia (CAP) in whom a 5-day antibiotic therapy would achieve clinical stability according to American Thoracic Society (ATS) criteria.
Methods |
Patients aged≥75 years, hospitalised for CAP between November 2018 and August 2019, were analysed retrospectively. The American Thoracic Society (ATS) clinical stability criteria (temperature≤37°C, heart rate≤100/min, respiratory rate≤24/min, systolic blood pressure≥90mmHg, oxygen saturation≥90% in room air) were assessed after five days of antibiotic therapy.
Results |
Seventy-five patients (mean age 88 years, 49% requiring oxygen therapy) were included. Six died, and at day 5, 36/69 (52%) fulfilled 4/5 stability criteria. The median duration of treatment was 9 days. In 28 patients (41%), it was ≤7 days.
Conclusion |
In 52% of elderly patients with CAP, a 5-day treatment regimen resulted in clinical stability.
Le texte complet de cet article est disponible en PDF.Keywords : Community-acquired pneumonia, Elderly, Antibiotic, Treatment duration
Plan
Vol 51 - N° 4
P. 377-379 - juin 2021 Retour au numéro
Article précédent
- Cotrimoxazole for community-acquired urinary tract infections leads to more adverse effects than fluoroquinolones
- C. Michelangeli, J. Courjon, E. Curlier, P.-M. Roger
- Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population
- Nathanael Lapidus, Juliette Paireau, Daniel Levy-Bruhl, Xavier de Lamballerie, Gianluca Severi, Mathilde Touvier, Marie Zins, Simon Cauchemez, Fabrice Carrat, for the SAPRIS-SERO study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?